Pulmonary Fibrosis

"Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.

Descriptor ID	D011658
MeSH Number(s)	C08.381.765
Concept/Terms	Pulmonary Fibrosis Pulmonary Fibrosis Pulmonary Fibroses Fibroses, Pulmonary Fibrosis, Pulmonary Alveolitis, Fibrosing Alveolitis, Fibrosing Alveolitides, Fibrosing Fibrosing Alveolitides Fibrosing Alveolitis Hamman-Rich Syndrome Hamman Rich Syndrome Syndrome, Hamman-Rich

Below are MeSH descriptors whose meaning is more general than "Pulmonary Fibrosis".

Diseases [C]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Pulmonary Fibrosis [C08.381.765]

Below are MeSH descriptors whose meaning is more specific than "Pulmonary Fibrosis".

Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pulmonary Fibrosis" by people in this website by year, and whether "Pulmonary Fibrosis" was a major or minor topic of these publications.

Bar chart showing 76 publications over 26 distinct years, with a maximum of 9 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	3	2	5
1996	0	1	1
1997	2	0	2
1998	1	0	1
2000	2	0	2
2001	1	1	2
2003	1	1	2
2004	4	0	4
2005	4	1	5
2006	2	2	4
2007	7	2	9
2008	4	0	4
2010	2	0	2
2012	3	1	4
2013	1	1	2
2015	2	0	2
2016	2	0	2
2017	3	1	4
2018	1	0	1
2019	2	1	3
2020	0	1	1
2021	0	1	1
2022	3	0	3
2023	3	0	3
2024	1	1	2
2025	5	0	5

Below are the most recent publications written about "Pulmonary Fibrosis" by people in Profiles.

Wang JM, Adegunsoye A, Pugashetti JV, Lee CT, Murray S, Mohan N, Nazemi N, Kang E, Chelala L, Kazerooni EA, Flaherty KR, Belloli EA, Sheth JS, O'Dwyer DN, Strek ME, Hatt CR, Han MK, Chung JH, Oldham JM. A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2025 Oct; 211(10):1785-1793.

View in: PubMed
Newton CA, Thenappan A, Liu GY, Yazbeck L, Lee CT, Pugashetti JV, Wang JM, White E, Flaherty KR, Belloli EA, Sheth JS, Mohan N, Nazemi N, Yu AR, Ghodrati S, Johannson KA, Marcoux V, Fisher JH, Assayag D, Manganas H, Khalil N, Kolb M, Morisset J, Garcia CK, Chua F, Strek ME, Khor YH, Adegunsoye A, Ryerson CJ, Molyneaux PL, Oldham JM. Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2025 Oct; 211(10):1867-1875.

View in: PubMed
Wang JM, Bose S, Murray S, Labaki WW, Kazerooni EA, Chung JH, Flaherty KR, Han MK, Hatt CR, Oldham JM. Quantitative Computed Tomography Measures of Lung Fibrosis and Outcomes in the National Lung Screening Trial. Ann Am Thorac Soc. 2025 Sep; 22(9):1314-1320.

View in: PubMed
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.

View in: PubMed
Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, Ogura T, Suda T, Wijsenbeek M, Berkowitz E, Elpers B, Kim S, Watanabe H, Fischer A, Maher TM. Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025 Feb; 211(2):230-238.

View in: PubMed
Wang JM, Araki T, Cottin V, Han MK, Oldham JM. Quantitative Imaging Methods in Combined Pulmonary Fibrosis and Emphysema. Chest. 2024 Dec; 166(6):1463-1472.

View in: PubMed
Adegunsoye A, Kropski JA, Behr J, Blackwell TS, Corte TJ, Cottin V, Glanville AR, Glassberg MK, Griese M, Hunninghake GM, Johannson KA, Keane MP, Kim JS, Kolb M, Maher TM, Oldham JM, Podolanczuk AJ, Rosas IO, Martinez FJ, Noth I, Schwartz DA. Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):401-423.

View in: PubMed
Kim JS, Montesi SB, Adegunsoye A, Humphries SM, Salisbury ML, Hariri LP, Kropski JA, Richeldi L, Wells AU, Walsh S, Jenkins RG, Rosas I, Noth I, Hunninghake GM, Martinez FJ, Podolanczuk AJ. Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis. Ann Am Thorac Soc. 2023 12; 20(12):1683-1693.

View in: PubMed
Aronson KI, Martin-Schwarze AM, Swigris JJ, Kolenic G, Krishnan JK, Podolanczuk AJ, Kaner RJ, Martinez FJ, Safford MM, Pinheiro LC. Validity and Reliability of the Fatigue Severity Scale in a Real-World Interstitial Lung Disease Cohort. Am J Respir Crit Care Med. 2023 07 15; 208(2):188-195.

View in: PubMed
Adegunsoye A, Newton CA, Oldham JM, Ley B, Lee CT, Linderholm AL, Chung JH, Garcia N, Zhang D, Vij R, Guzy R, Jablonski R, Bag R, Voogt RS, Ma SF, Sperling AI, Raghu G, Martinez FJ, Strek ME, Wolters PJ, Garcia CK, Pierce BL, Noth I. Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts. Nat Commun. 2023 03 17; 14(1):1489.

View in: PubMed

People

Explore

Similar Concepts

Top Journals